Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed cell therapy and biopharmaceutical specialist Dr Bradley Glover as the immune-oncology company’s chief operating officer, effective immediately.
Dr Glover has extensive experience in the cell therapy, biopharmaceuticals, diagnostics, venture capital, finance, research and development and education spheres.
He has demonstrated expertise in deal negotiations, strategic collaborations, acquisitions and licensing agreements and has made academic contributions including published research articles in biochemistry and genetics.
“Profound industry knowledge and experience”
"Dr Glover is a very welcome addition to Imugene and our executive team,” Imugene CEO and managing director Leslie Chong said.
“His extensive expertise, especially in operations and strategic planning, will be invaluable as we advance our technology pipeline.
“Dr Glover's profound industry knowledge and experience positions him well within our world-class team.”
Dr Glover holds a PhD in Biochemistry & Molecular Genetics from the University of Colorado and an MBA in Marketing & Finance from the Rady School of Management, University of California San Diego.
He previously held the position of executive vice president and chief operating officer at Celularity, playing a pivotal role in strategic planning, business development and technical operations.
Dr Glover also served as vice president and head of corporate strategy and operations at cell therapy company Kite Pharma, overseeing global corporate strategy, planning, portfolio management, product and program management and global business transformation.